ADCT Stock Holds $219M Cash at a $144M Valuation
ADC Therapeutics (ADCT) stock analysis: trading below $219M cash — valuation breakdown
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down ADC Therapeutics SA (ADCT) and its high-stakes biopharma turnaround driven by flagship oncology drug ZYNLONTA and upcoming Phase 3 LOTIS-7 clinical trial data. With shares trading at a $144 million market capitalization below its $219.1 million cash balance, the key question for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.